COMP <GO>
SHC vs LLY // PIOTROSKI F-SCORE QUALITY
Sotera Health Company (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SHC 3
— LLY 12
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $18.15 (-2.94%) • MKT CAP: $5.34B
piotroski-score
8/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.50% | 83.64% | -28.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 32.36% | -29.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.5x | 36.4x | -2.92 | SHC | /valuation <GO> |
| Free Cash Flow Yield | 2.80% | 2.30% | +0.50 | SHC | /fcf-yield <GO> |
| Operating Margin | 8.20% | 40.21% | -32.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 6.70% | 31.90% | -25.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 45.51% | -39.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.56 | 9.29 | -7.73 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 77.9 | -29.94 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.51 | +0.59 | SHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.7x | 26.3x | +37.45 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.34B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SHC REV | LLY REV | SHC GROSS % | LLY GROSS % | SHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.16B | $65.18B | 55.5% | 83.0% | $149.2M | $16.81B |
| FY 2024 | $1.10B | $45.04B | 54.7% | 81.3% | $45.1M | $8.82B |
| FY 2023 | $1.05B | $34.12B | 44.0% | 79.3% | -$194.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SHC // BETA 1.10
LLY // BETA 0.51